Equillium, Inc. Dividend History (EQ)

🤑 Equillium, Inc. has distributed a total of 12 dividends from 2006 to 2009
📈 During this 3 period their dividend has seen a 37.50% increase in the payout amount

About

About Equillium, Inc.

Equillium, Inc. is a biotechnology company founded in 2017 by Krishna Polu, Bruce Steel, and Stephen Connelly. The company is headquartered in La Jolla, California, and focuses on developing innovative treatments for severe autoimmune and inflammatory diseases. Equillium's lead product candidate, itolizumab, is a monoclonal antibody designed to modulate the activity of the immune system and address conditions such as lupus nephritis, uncontrolled asthma, and more. As a clinical-stage biotech firm, Equillium collaborates with various research institutions to advance its pipeline and validate its therapeutic approaches. The company went public in 2018, trading on the Nasdaq under the ticker symbol EQ. While revenue streams are primarily research and development-based at this stage, Equillium's commitment to addressing unmet medical needs positions it as a promising player in the biotech industry.

Website: https://www.equilliumbio.com

Address: 2223 Avenida De La Playa, La Jolla, CA, 92037

Phone: (858) 412-5302

Other companies you might be interested in

Apple Inc.

Microsoft Corporation

Exxon Mobil Corporation

Verizon Communications Inc.

AT&T Inc.

Chevron Corporation

Company News

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

The graft versus host disease market is experiencing significant growth, driven by the adoption of branded therapies, a strong pipeline with the anticipated launch of over 10 new drugs, and increased awareness of GvHD management. Innovative treatments and ongoing research are expected to further expand market opportunities.

GlobeNewswire Inc. · Published on Sun Sep 22 2024

Other companies featured in this article: TAK SNDX MESO INCY PFE BMY MCRB

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy

Vivtex and Equillium have entered a research collaboration to develop an optimized oral version of Equillium's EQ302, a bi-specific peptide inhibitor of IL-15 and IL-21, for the treatment of gastrointestinal disorders.

GlobeNewswire Inc. · Published on Mon Sep 16 2024

Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates

Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research · Published on Thu May 09 2024

Other companies featured in this article: INO

Previous Payouts (12)

The most recent dividend Equillium, Inc. paid out was on June 30, 2009 (5640 days ago) for $0.6875 per share

Pay Date	Amount
June 30, 2009	$0.6875
March 31, 2009	$0.6875
December 31, 2008	$0.6875
September 30, 2008	$0.6875
June 30, 2008	$0.6875
March 31, 2008	$0.6875
December 31, 2007	$0.625
September 30, 2007	$0.625
June 30, 2007	$0.625
March 31, 2007	$0.5
December 31, 2006	$0.5
September 30, 2006	$0.5

Dividend data last updated Sun, 08 Dec 2024 20:11:50 GMT UTC